Medunik Canada
Member of Duchesnay Pharmaceutical Group
  • Press Room
    • Archives
    • Media Inquiries
  • Careers
  • Contact Us
  • United States
  • FR
1 844 433-4441
  • About Us
    • Advisory Board
  • Rare Diseases
    and Orphan Drugs
    • What is a rare disease?
    • What is an orphan drug
    • Drug approval process
  • Therapeutic Areas
    and Products
    • Therapeutic Areas
    • Products
    • Patient Support Program
  • Press Room
    • Archives
    • Media Inquiries
  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Product Return Policy

Press Room: Archives

Filters
Senior management team takes over ownership of Quebec-based multinational pharmaceutical group Duchesnay

10 November 2021

BLAINVILLE, QUEBEC – November 10, 2021 – The ownership of Duchesnay and its affiliated pharmaceutical companies, based in Blainville, Quebec, have been acquired by its senior management headed by Éric Gervais, President, after more than 25 years as Executive Vice-President. Management has acquired these successful businesses from Pierre Boivin and his family after he expressed his desire to step back to pursue other interests.

Read more

Médunik Canada once again receives Notice of Compliance from Health Canada for Ruzurgi® (amifampridine) following review ordered by court ruling

29 June 2021

BLAINVILLE, Quebec (Canada) – June 29, 2021 – Médunik Canada is pleased to announce that Health Canada has reissued the approval (Notice of Compliance) for Ruzurgi® (amifampridine), for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients six years of age or older and has resumed supply in Canada.

Read more

Ruzurgi® Now Available to Canadian Lambert-Eaton Myasthenic Syndrome (LEMS) Patients

25 September 2020

BLAINVILLE, Quebec (Canada) – September 25, 2020 – Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that its new orphan disease product Ruzurgi® (amifampridine) is now commercially available to Canadian patients.

Read more

Médunik Canada Expands its Orphan Disease Portfolio by Receiving Market Authorization for Ruzurgi®

18 August 2020

BLAINVILLE, Quebec (Canada) – August 18, 2020 – Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that our orphan disease portfolio just expanded further with the recent addition of a new drug. Health Canada has issued a Notice of Compliance (NOC) for Ruzurgi® (amifampridine), a drug indicated for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients 6 years of age or older.

Read more

Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

16 January 2019

BLAINVILLE, QC (CANADA), January 16, 2019 — Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, is proud to announce the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.  

Read more

Medunik Canada is pleased to announce the launch of NORD Founder Abbey Meyers’ memoir, “Orphan Drugs: A Global Crusade”

16 February 2016

BLAINVILLE, QC (Canada) – February 16, 2016 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce the launch of Orphan Drugs: A Global Crusade, the memoir of Abbey Meyers, founder and past President of the National Organization for Rare Disorders (NORD). In anticipation of Rare Disease Day on February 29th, Medunik Canada would like to bring to light the hard work and commitment of orphan drug crusaders, like Ms. Meyers.

Read more

PHEBURANE® now available for distribution in Canada through Medunik Canada

30 March 2015

BLAINVILLE, QC (Canada) – March 30th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE® is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

Read more

Medunik Canada is pleased to announce that Health Canada has granted market authorization for Pheburane®

27 January 2015

BLAINVILLE, QC (Canada) – January 27th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) for PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of urea cycle disorders (UCD), involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. Canadians living with a urea cycle disorder will now have access to an approved tasteless medication for the treatment of this metabolic disease.

Read more

Medunik Canada announces Health Canada Priority Review of PHEBURANE® indicated for the treatment of Urea Cycle Disorders (UCD)

24 September 2014

BLAINVILLE, QC (Canada) – September 24th, 2014 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, announces that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of Urea Cycle Disorders (UCD), was granted a Priority Review Status by Health Canada. This treatment will provide Canadians living with a urea cycle disorder access to a lower-cost alternative solution for the treatment of this metabolic disease.

Read more

Medunik Canada and Lucane Pharma conclude an exclusive licence and collaboration agreement

04 December 2013

Blainville, Quebec (Canada) – December 4, 2013 - Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement. Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase. This therapeutic option is taste-free, which facilitates medication and favours compliance to treatment.

Read more

Page 1 of 2

  • 1
  • 2
  • Forgot your username?
  • Forgot your password?

Medunik Canada Logo

1 844 433-4441

950, boul. Michèle-Bohec
Blainville (Québec) Canada
J7C 5E2
Connect with us
  • About Us
  • Rare Diseases and Orphan Drugs
  • Therapeutic Areas and Products
  • Press Room
  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Product Return Policy
©2023. Medunik Canada Inc. All rights reserved
This site is intended for Canadian residents only. Medical practices, products and/or regulations may differ from one country to another. As a result, the medical and/or product information on this site is not appropriate for use outside of Canada. The information is not meant to suggest any medical course of action. Rather, it is intended to inform and to raise awareness so that these issues can be discussed with qualified healthcare professionals.